Methods
SECONDARY
A detailed description of the design and primary results of the EMPA-HEART CardioLink-6 trial has been published previously [Given that the median baseline LVMi for the empagliflozin-assigned group was 58 kg/mOur secondary analyses included assessment of the relationship between baseline LVMi and changes in left ventricular end-systolic volume indexed to body surface area (LVESVi), left ventricular end-diastolic volume indexed to body surface area (LVEDVi), and left ventricular ejection fraction (LVEF) from baseline to 6-months. We also tested the associations between baseline LVMi and baseline left ventricular end-systolic volume (LVESV), LVESVi, left ventricular end-diastolic volume (LVEDV), LVEDVi, and LVEF.